Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for OrthoPediatrics Corp. (KIDS:NASDAQ), powered by AI.
OrthoPediatrics Corp. is currently trading at $18.53. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for OrthoPediatrics Corp. on Alpha Lenz.
OrthoPediatrics Corp.'s P/E ratio is -11.0.
“OrthoPediatrics Corp. trades at a P/E of -11.0 (undervalued) with modest ROE of -11.3%. 3Y revenue CAGR of 24.6% highlights clear growth momentum.”
Ask for details →OrthoPediatrics Corp. is a specialized orthopedic medical device company focusing on the pediatric market. The company is dedicated to advancing the field of pediatric orthopedics by developing and marketing products specifically designed to treat musculoskeletal conditions in children. OrthoPediatrics Corp.'s product portfolio includes a wide range of innovative solutions for trauma and deformity correction, complex spine conditions, and sports medicine. These products are crucial for ensuring that children receive appropriate and tailored care, which can significantly impact their long-term physical development. Primarily serving hospitals and orthopedic surgeons, OrthoPediatrics plays a critical role in advancing medical care for younger demographics. Marketed globally, the company's products support a sometimes underrepresented segment within the medical device industry, emphasizing safety, efficacy, and child-specific design. By focusing exclusively on pediatric orthopedics, OrthoPediatrics Corp. holds a unique position in the health care market, addressing a specialized need and striving to improve the quality of life and outcomes for young patients worldwide.
“OrthoPediatrics Corp. trades at a P/E of -11.0 (undervalued) with modest ROE of -11.3%. 3Y revenue CAGR of 24.6% highlights clear growth momentum.”
Ask for details →OrthoPediatrics Corp. (ticker: KIDS) is a company listed on NASDAQ in the Healthcare sector (Medical Devices). It has approximately 562 employees. Market cap is $435M.
The current price is $18.53 with a P/E ratio of -10.96x and P/B of 1.25x.
ROE is -11.31% and operating margin is -12.27%. Annual revenue is $236M.